BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
M Reig, A Forner, J Rimola, J Ferrer-Fàbrega… - Journal of …, 2022 - Elsevier
There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
[PDF][PDF] Emerging immunotherapy for HCC: A guide for hepatologists
HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …
Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
[HTML][HTML] Hepatocellular carcinoma in 2021: an exhaustive update
CA Philips, S Rajesh, DC Nair, R Ahamed… - Cureus, 2021 - ncbi.nlm.nih.gov
Primary liver cancer is a challenging global health concern with an estimated more than a
million persons to be affected annually by the year 2025. The commonest type is …
million persons to be affected annually by the year 2025. The commonest type is …
Breakthroughs in hepatocellular carcinoma therapies
Several breakthroughs in hepatocellular carcinoma (HCC) therapy across tumor stages
provide hope to improve its dismal prognosis. Although surgical and local ablative therapies …
provide hope to improve its dismal prognosis. Although surgical and local ablative therapies …
[HTML][HTML] Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning
YQ Jiang, SE Cao, S Cao, JN Chen, GY Wang… - Journal of cancer …, 2021 - Springer
Purpose Microvascular invasion (MVI) is a valuable predictor of survival in hepatocellular
carcinoma (HCC) patients. This study developed predictive models using eXtreme Gradient …
carcinoma (HCC) patients. This study developed predictive models using eXtreme Gradient …
Targeted and immune-based therapies for hepatocellular carcinoma
Treatment options for patients with hepatocellular carcinoma are rapidly changing based on
positive results from phase 3 trials of targeted and immune-based therapies. More agents …
positive results from phase 3 trials of targeted and immune-based therapies. More agents …
Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised …
NV Violi, R Duran, B Guiu, JP Cercueil… - The lancet …, 2018 - thelancet.com
Background Radiofrequency ablation is the recommended treatment for patients with
hepatocellular carcinoma who have lesions smaller than 3 cm and are therefore not …
hepatocellular carcinoma who have lesions smaller than 3 cm and are therefore not …
New concepts in the treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the third most common cause of cancer‐related death
and occurs mainly in the context of chronic liver disease at cirrhosis stage. The Barcelona …
and occurs mainly in the context of chronic liver disease at cirrhosis stage. The Barcelona …